BR0206986A - Métodos e composições para modular a regulação da resposta a citotóxica do linfócito por fator inibitório de migração de macrófago - Google Patents

Métodos e composições para modular a regulação da resposta a citotóxica do linfócito por fator inibitório de migração de macrófago

Info

Publication number
BR0206986A
BR0206986A BR0206986-5A BR0206986A BR0206986A BR 0206986 A BR0206986 A BR 0206986A BR 0206986 A BR0206986 A BR 0206986A BR 0206986 A BR0206986 A BR 0206986A
Authority
BR
Brazil
Prior art keywords
mif
tumor
methods
treated
macrophage migration
Prior art date
Application number
BR0206986-5A
Other languages
English (en)
Inventor
Riichiro Abea Abe
Richard Bucala
Christine Metz
Original Assignee
Cytokine Pharmasciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokine Pharmasciences Inc filed Critical Cytokine Pharmasciences Inc
Publication of BR0206986A publication Critical patent/BR0206986A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"MéTODOS E COMPOSIçõES PARA MODULAR A REGULAçãO DA RESPOSTA CITOTóXICA DO LINFóCITO POR FATOR INIBITóRIO DE MIGRAçãO DE MACRóFAGO". é descrita a regulação da expressão da atividade de CTL através de fator inibitório de migração de macrófago (MIF). Em um modelo de camundongo empregando o tumor EL4, esplenócitos cultivados a partir de camundongos com tumor iniciado secretam níveis elevados de MIF seguindo estimulação de antígeno in vitro. Esplenócitos paralelos tratados com mAb anti-MIF de neutralização mostraram um aumento significante na resposta CTL contra células de tumor comparadas às culturas de controle tratadas com mAb, com expressão elevada de IFN<sym>. A histologia de tumores a partir de animais tratados com anti-MIF mostrou aumentos na infiltração de ambas as células T CD4¬ +¬ e CD8¬ +¬, bem como células de tumor apoptótico, consistente com a argumentação observada de atividade CTL in vivo por anti-MIF, a qual estava associada com expressão intensificada da cadeias <sym>~ c~ comuns do receptor IL-2 que medeia célula T CD8¬ +¬ sobreviventes. Células CD8¬ +¬ de camundongos contendo tumor tratado com anti-MIF mostraram migração aumentada para tumores de camundongos de controle. Métodos para aumentar um resposta CTL através de inibição de MIF são descritos.
BR0206986-5A 2001-01-12 2002-01-14 Métodos e composições para modular a regulação da resposta a citotóxica do linfócito por fator inibitório de migração de macrófago BR0206986A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26091401P 2001-01-12 2001-01-12
PCT/US2002/000536 WO2002067862A2 (en) 2001-01-12 2002-01-14 Regulation of the ctl response by macrophage migration inhibitory factor

Publications (1)

Publication Number Publication Date
BR0206986A true BR0206986A (pt) 2005-11-01

Family

ID=22991181

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0206986-5A BR0206986A (pt) 2001-01-12 2002-01-14 Métodos e composições para modular a regulação da resposta a citotóxica do linfócito por fator inibitório de migração de macrófago

Country Status (8)

Country Link
US (1) US20020114812A1 (pt)
EP (1) EP1465660A4 (pt)
JP (1) JP2004531237A (pt)
CN (1) CN1842346A (pt)
BR (1) BR0206986A (pt)
CA (1) CA2434671A1 (pt)
MX (1) MXPA03006275A (pt)
WO (1) WO2002067862A2 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY27304A1 (es) 2001-05-24 2002-12-31 Avanir Pharmaceuticals Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
TW200418829A (en) 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
AU2005216236A1 (en) * 2004-02-25 2005-09-09 The United States Of America As Represented By The Department Of Veterans Affairs Methods for diagnosing and treating bladder cancer
US20060229314A1 (en) 2005-03-24 2006-10-12 Jagadish Sircar Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors
MX2010010198A (es) * 2008-03-20 2010-12-21 Carolus Therapeutics Inc Metodos para tratamiento de inflamacion.
US20110070184A1 (en) * 2008-03-24 2011-03-24 Carolus Therpeutics, Inc. Methods and compositions for treating atherosclerosis and related condidtions
US20100183598A1 (en) * 2008-11-12 2010-07-22 Carolus Therapeutics, Inc. Methods of treating cardiovascular disorders
NZ723731A (en) * 2011-04-08 2020-05-29 Baylor College Medicine Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
WO2016156489A1 (en) * 2015-03-31 2016-10-06 Baxalta GmbH Dosage regimen for anti-mif antibodies
CN105087610A (zh) * 2015-09-11 2015-11-25 中国科学院海洋研究所 文蛤巨噬细胞迁移抑制因子基因及其编码蛋白和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6645493B1 (en) * 1993-05-17 2003-11-11 The Picower Institute For Medical Research Composition containing anti-MIF antibody
US6774227B1 (en) * 1993-05-17 2004-08-10 Cytokine Pharmasciences, Inc. Therapeutic uses of factors which inhibit or neutralize MIF activity
AU1235601A (en) * 1999-10-29 2001-05-14 Cytokine Pharmasciences, Inc. Compounds having mif antagonist activity

Also Published As

Publication number Publication date
CN1842346A (zh) 2006-10-04
WO2002067862A2 (en) 2002-09-06
JP2004531237A (ja) 2004-10-14
WO2002067862A3 (en) 2004-05-21
CA2434671A1 (en) 2002-09-06
US20020114812A1 (en) 2002-08-22
EP1465660A4 (en) 2005-09-21
EP1465660A2 (en) 2004-10-13
MXPA03006275A (es) 2005-09-08

Similar Documents

Publication Publication Date Title
BR0206986A (pt) Métodos e composições para modular a regulação da resposta a citotóxica do linfócito por fator inibitório de migração de macrófago
Tsung et al. Lessons from Coley's toxin
DK1549353T3 (da) Anvendelse af alfa(1,3)galactosyltransferaseudtrykkende allogene tumorceller til vaccination mod tumorer
ECSP055739A (es) Anticuerpos de neutralización contra gdf-8, y sus usos
BR0108977A (pt) Compostos azacìclicos para uso no tratamento de doenças relaciondas com serotonina
IL180612A0 (en) Materials and methods for immune system stimulation
WO2011146828A3 (en) Cancer treatment
DK0777499T3 (da) Levende vaccine til behandling af tumorsygdomme
ES2183815T3 (es) Quimioterapia para el cancer.
ATE287958T1 (de) Verbesserte krebstherapie
MX2020009150A (es) Anfifilos de cpg y usos de los mismos.
ATE512668T1 (de) Allogenes tumortherapeutikum
FI950439A (fi) 3&#39;-atsido-3&#39;-deoksitymidiinin kontrolloidusti vapauttavat farmaseuttiset valmisteet ja käyttömenetelmät
AR052152A1 (es) Producto farmaceutico para el tratamiento preventivo y terapeutico de trastornos del sueno
BRPI0417762A (pt) organismo vivo, um plasmodium, método para inocular um hospedeiro vertebrado contra malária, composição de vacina, uso de um organismo vivo, um plasmodium, e, método de produção de uma composição de vacina
BR0211400A (pt) Tratamento de distrofia muscular com células de sangue do cordão
Nikkhah Nature as an ideal rhythm model for optimal cardiovascular physiology and health
EP1556513A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES MEDIATED BY THE HUMANE PAPILLOMA VIRUS
BR0308810A (pt) Células hospedeiras tendo propriedades melhoradas de sobrevivência celular e métodos para gerar tais células
Watanabe et al. Inhibitory effect of trehalose dimycolate (TDM) and its stereoisometric derivatives, trehalose dicorynomycolates (TDCMs), with low toxicity on lung metastasis of tumour cells in mice
WO2003104397A3 (en) ANTISENSE MODULATION OF PROTEIN KINASE GR 6 EXPRESSION
BR9915330A (pt) Método para imunizar uma ave contra uma doença
GEP19991604B (en) Human Follicle Stimulating Hormone Receptor
ES2138602T3 (es) Agente terapeutico para la amenaza de aborto.
MXPA02009781A (es) Isoformas de esfingosina cinasa tipo 2 de mamifero, clonacion, expresion y metodos de uso de las mismas.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A,6A,7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2025 DE 27/10/2009.